TR201909029T4 - Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler. - Google Patents

Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler. Download PDF

Info

Publication number
TR201909029T4
TR201909029T4 TR2019/09029T TR201909029T TR201909029T4 TR 201909029 T4 TR201909029 T4 TR 201909029T4 TR 2019/09029 T TR2019/09029 T TR 2019/09029T TR 201909029 T TR201909029 T TR 201909029T TR 201909029 T4 TR201909029 T4 TR 201909029T4
Authority
TR
Turkey
Prior art keywords
stable compositions
storage containing
containing rifaximin
rifaximin
rifaximin alpha
Prior art date
Application number
TR2019/09029T
Other languages
English (en)
Inventor
Xaver Schwarz Franz
Pichler Arthur
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55637249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201909029(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of TR201909029T4 publication Critical patent/TR201909029T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Farmasötik bileşim olup, (A) polimorfik ? formunda rifaksimin ve (B) ağırlıkça %3?ten daha düşük bir su içeriğine sahip emici ajan içermesidir. Burada (A) rifaksiminin (B) emici ajana ağırlık oranı 1:1 ila 3:1?dir ve burada farmasötik bileşim diğer polimorfik rifaksimin formlarını özellikle içermez.
TR2019/09029T 2016-03-24 2017-03-22 Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler. TR201909029T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16162417 2016-03-24

Publications (1)

Publication Number Publication Date
TR201909029T4 true TR201909029T4 (tr) 2019-07-22

Family

ID=55637249

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09029T TR201909029T4 (tr) 2016-03-24 2017-03-22 Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler.

Country Status (9)

Country Link
US (1) US10842782B2 (tr)
EP (2) EP3373914B2 (tr)
AU (1) AU2017237469B2 (tr)
CA (1) CA3003108C (tr)
ES (1) ES2738024T5 (tr)
HU (1) HUE044432T2 (tr)
PL (1) PL3373914T5 (tr)
TR (1) TR201909029T4 (tr)
WO (1) WO2017162726A1 (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
PT3546464T (pt) 2014-05-12 2020-08-05 Alfasigma Spa Preparação e utilização da forma cristalina tau de rifaximina solvatada com degme
US10576065B2 (en) 2016-03-24 2020-03-03 Sandoz Ag Pharmaceutical composition containing rifaximin alpha and delta
CN113747654B (zh) * 2020-05-27 2023-08-04 宏启胜精密电子(秦皇岛)有限公司 柔性电路板及其制作方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1883776U (de) * 1963-07-31 1963-11-28 Schering Ag Tablettendurchdruckpackung.
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2014091432A1 (en) * 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
US9018225B1 (en) * 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof

Also Published As

Publication number Publication date
WO2017162726A1 (en) 2017-09-28
EP3373914B2 (en) 2022-06-01
US20190008838A1 (en) 2019-01-10
AU2017237469B2 (en) 2018-06-28
ES2738024T3 (es) 2020-01-17
EP3536311B1 (en) 2021-12-22
EP3373914A1 (en) 2018-09-19
ES2738024T5 (es) 2022-10-24
EP3536311A1 (en) 2019-09-11
CA3003108A1 (en) 2017-09-28
CA3003108C (en) 2018-08-14
PL3373914T5 (pl) 2022-10-17
AU2017237469A1 (en) 2018-06-07
US10842782B2 (en) 2020-11-24
EP3373914B1 (en) 2019-04-24
HUE044432T2 (hu) 2019-10-28
PL3373914T3 (pl) 2019-10-31

Similar Documents

Publication Publication Date Title
CL2017000240A1 (es) Compuestos activos hacia bromodominios
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CO2018008707A2 (es) Inhibidores de la proteína quinasa 1 que interactúa con el receptor
UA109122C2 (uk) Синергічна гербіцидна композиція, яка містить амінопіралід і 2,4-дихлорфеноксіоцтову кислоту
GB2540709A (en) Using synthetic acid compositions as alternatives to conventional acids in the oil and gas industry
MX2016007572A (es) Productos resistentes al agua usando una emulsion de cera.
MX355284B (es) Composiciones para cuidado oral que comprenden carbonato de calcio y arcilla.
MX378946B (es) Composiciones aglomerantes y métodos para fabricación y utilización de las mismas.
MX2016011897A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
EA201400537A1 (ru) 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА
MX2016007838A (es) Composiciones para el cuidado oral que contienen carbonato de calcio y silice.
BR112014004263A2 (pt) composições fixadoras de cabelo
EA201690036A1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
MX386117B (es) Composiciones líquidas acuosas.
BR112016007068A2 (pt) ?composições cosméticas?
BR112014002940A2 (pt) uso e composição agroquímica de dibutilamidas de ácido carboxílico
DOP2016000007A (es) Pirazolpiridinas sustituidas
BR112016005589B8 (pt) Composição farmacêutica líquida, e, uso da mesma
MX381026B (es) Composición de limpieza con mejor disponibilidad del agente de beneficio.
JP2015518492A5 (tr)
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
MX2017006423A (es) Composición de caucho de nitrilo, composición de látex de caucho de nitrilo altamente saturado, y caucho reticulado.
IN2013CH06132A (tr)
PH12018501593A1 (en) Plasterboard
MX2016006616A (es) Mezcla reductora de grietas para composiciones cementosas.